{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-015854","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.753895+00:00","generated_at":"2026-06-29T21:42:46.606295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M","bullets":["Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.","Received 415 LUPKYNIS patient start forms in Q2, over 800 YTD; >50% converted to therapy.","Cash and investments $323.7M; 2021 LUPKYNIS net revenue guidance $40-50M.","Otsuka filed MAA in EU for voclosporin; Aurinia eligible for up to $30M milestones plus royalties.","Appointed Dr. Brinda Balakrishnan to Board; Lancet published AURORA-1 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-015854","json":"https://secwatch.observer/filing/0001628280-21-015854.json","markdown":"https://secwatch.observer/filing/0001628280-21-015854.md","text":"https://secwatch.observer/filing/0001628280-21-015854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/0001628280-21-015854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/auph-20210805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:42:46.606295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}